Prevention of liver cancer: basic and clinical aspects.
- Author:
Hisataka MORIWAKI
1
Author Information
1. Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan. hmori@cc.gifu-u.ac.jp
- Publication Type:Review ; Research Support, Non-U.S. Gov't
- Keywords:
AFP, alpha-fetoprotein;
HBV, hepatitis B virus;
HCV, hepatitis C virus;
RXR, retinoid X receptor
- MeSH:
Animals;
Chemoprevention;
Hepatitis B/complications/drug therapy;
Human;
Liver Neoplasms/etiology/*prevention & control;
Retinoids/*therapeutic use
- From:Experimental & Molecular Medicine
2002;34(5):319-325
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cancer prevention is a challenging project both in the basic and clinical medicine. In particular, prevention of liver cancer is the most urgent task in countries where the incidence of hepatitis virus-related liver cancer is rising. As reviewed in this article, liver cancer is going to be the first cancer that will be actually prevented by primary and secondary interventions. Even the improvement of absolute survival of the patients can be expected by successful prevention, as already demonstrated in a few clinical trials. Thus, prevention of liver cancer is promising to provide not only cost-effectiveness by morbidity reduction but also cost-benefit by mortality improvement.
